Effectiveness of oxaliplatin desensitization protocols

Clinical and Translational Oncology

Volumn 15, Issue 3, 2013, Pages 219-225

  Cortijo Cascajares, Susana ^a   Nacle López, Inmaculada ^b   García Escobar, Ignacio ^a   Aguilella Vizcaíno, María José ^a   Herreros De Tejada, Alberto ^a   Cortés Funes Castro, Hernán ^a   Calleja Hernández, Miguel Ángel ^c  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b Hospital San Juan de la Cruz   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

Author keywords

Desensitization; Hypersensitivity reactions; Oxaliplatin

Indexed keywords

BEVACIZUMAB; CAPECITABINE PLUS OXALIPLATIN; FLUOROURACIL; OXALIPLATIN;

ADULT; ANGIONEUROTIC EDEMA; BRONCHOSPASM; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL PROTOCOL; COLORECTAL CANCER; CONTROLLED STUDY; DESENSITIZATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EDEMA; ERYTHEMA; FEMALE; HOT FLUSH; HUMAN; HYPOTENSION; MACULOPAPULAR RASH; MALE; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PRURITUS; RETROSPECTIVE STUDY; REVIEW; SKIN TEST; URTICARIA;

EID: 84878555966     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-012-0909-9     Document Type: Review

References (32)

1. Lee C, Gianos M, Klaustermeyer WB (2009) Diagnosis and management of hypersensitivity reactions related to common cancer chemotherapy agents. Ann Allergy Asthma Immunol 102:179-187
2. Syrigou E, Syrigos K, Saif MW (2008) Hypersensitivity reactions to oxaliplatin and other antineoplastic agents. Curr Allergy Asthma Rep 8:56-62
3. Pagani M (2010) The complex clinical picture of presumably allergic side effects to cytostatic drugs: symptoms, pathomechanism, reexposure, and desensitization. Med Clin North Am 94:835-852
4. Polyzos A, Tsavaris N, Gogas H, Souglakos J, Vambakas L, Vardakas N, et al. (2008) Clinical features of hypersensitivity reactions to oxaliplatin: a 10-year experience. Oncology 76:36-41
5. Medioni J, Coulon MA, Morere JF, Hennebelle F, Piperno-Neumann S, Breau JL (1999) Anaphylaxis after oxaliplatin. Ann Oncol 10:610
6. De Vries RS, Mattijssen EJ, van Sorge AA (2006) Serious delayed hypersensitivity reaction to oxaliplatin. Ann Oncol 17:1723-1724
7. Potenza S, Nasti G, Alessandro O, Filippelli A, Rossi F, Capuano A (2010) Severe respiratory symptoms to oxaliplatin infusion: a case report of delayed hypersensitivity reaction. Investig New Drugs 28:185-186
8. Köhlmoos C, Marquardt GG, Brinkmann D, Meier K (2008) Allergic reactions to oxaliplatin therapy - an overview. Eur J Oncol Pharm 2:27-28
9. Siu S, Chan R, Au G (2006) Hypersensitivity reactions to oxaliplatin: experience in a single institute. Ann Oncol 17:259
10. Shao YY, Hu FC, Liang JT, Chiu WT, Cheng AL, Yang CH (2010) Characteristics and risk factors of oxaliplatin-related hypersensitivity reactions. J Formosan Med Assoc 109:362-368
11. Kim BH, Bradley T, Tai J, Budman DR (2009) Hypersensitivity to oxaliplatin: an investigation of incidence and risk factors, and literature review. Oncology 76:231-238
12. Mori Y, Nishimura T, Kitano T, Yoshimura K, Matsumoto S, Kanai M, et al. (2010) Oxaliplatin-free interval as a risk factor for hypersensitivity reaction among colorectal cancer patients treated with FOLFOX. Oncology 79:136-143
13. Bhargava P, Gammon D, McCormick MJ (2004) Hypersensitivity and idiosyncratic reactions to oxaliplatin. Cancer 100:211-212
14. Brandi G, Pantaleo M, Galli C, Falcone A, Antonuzzo A, Mordenti P, et al. (2003) Hypersensitivity reactions related to oxaliplatin (OHP). Br J Cancer 89:477-481
15. Kidera Y, Satoh T, Ueda S, Okamoto W, Okamoto I, Fumita S, et al. (2011) High-dose dexamethasone plus antihistamine prevents colorectal cancer patients treated with modified FOLFOX6 from hypersensitivity reactions induced by oxaliplatin. Int J Clin Oncol. doi: 10.1007/s10147-010-0170-6:1-6
16. Maindrault-Goebel F, André T, Tournigand C, Louvet C, Perez-Staub N, Zeghib N, et al. (2005) Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients. Eur J Cancer 41:2262-2267
17. Thomas RR, Quinn MG, Schuler B, Grem JL (2003) Hypersensitivity and idiosyncratic reactions to oxaliplatin. Cancer 97:2301-2307
18. Tonini G, Santini D, Vincenzi B, Borzomati D, Dicuonzo G, La Cesa A, et al. (2002) Oxaliplatin may induce cytokine-release syndrome in colorectal cancer patients. J Biol Regul Homeost Agents 16:105-109
19. Ulrich-Pur H, Fiebiger WCC, Schüll B, Kornek GV, Scheithauer W, Raderer M (2000) Oxaliplatin-induced fever and release of IL-6. Oncology 59:187-189
20. Wilson C, Purcell C, Seaton A, Oladipo O, Maxwell PJ, O'Sullivan JM, Wilson R, Johnston PG, Waugh D (2012) Chemotherapy-induced CXC-chemokine/CXC- chemokine Receptor signaling in metastatic prostate cancer cells confers resistance to oxaliplatin through potentiation of nuclear factor-kappaB transcription and evasion of apoptosis. J Pharmacol Exp Ther 327:746-759
21. Kast R, Scheuerle A, Wirtz C, Karpel-Massler G, Halatsch ME (2011) The rationale of targeting neutrophils with dapsone during glioblastoma treatment. Anti Cancer Agents Med Chem 11:756-761
22. Edmondson DA, Gruling BJ, Urmanski AM, Wong SJ, Levy MB (2007) Oxaliplatin hypersensitivity: case report and successful repeat desensitization. Am J Ther 14:116-118
23. Gammon D, Bhargava P, McCormick MJ (2004) Hypersensitivity reactions to oxaliplatin and the application of a desensitization protocol. Oncologist 9:546
24. Meyer L, Zuberbier T, Worm M, Oettle H, Riess H (2002) Hypersensitivity reactions to oxaliplatin: cross-reactivity to carboplatin and the introduction of a desensitization schedule. J Clin Oncol 20:1146
25. Castells MC, Tennant NM, Sloane DE, Ida Hsu F, Barrett NA, Hong DI, et al. (2008) Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol 122:574-580
26. Habert H, Castagne V (2009) Management of hypersensitivity to oxaliplatin at the Paul Brousse hospital pharmacy department: desensitization protocol and clinical impact. Pharm World Sci 31:96-97
27. Syrigou EI, Karapanagiotou EM, Alamara CV, Boura PG, Saif MW, Syrigos KN (2009) Hypersensitivity reactions to oxaliplatin: a retrospective study and the development of a desensitization protocol. Clin Colorectal Cancer 8:106-109
28. Gottlieb GR, Bordoni RE, Lawhead RA Jr, Feinberg BA (2010) Successful outpatient desensitization of cancer patients with hypersensitivity reactions to chemotherapy. Community Oncol 7:452-457
29. Herrero T, Tornero P, Infante S, Fuentes V, Sanchez M, De Barrio M, et al. (2006) Diagnosis and management of hypersensitivity reactions caused by oxaliplatin. J Investig Allergol Clin Immunol 16:327
30. Gastaminza G, de la Borbolla JM, Goikoetxea MJ, Escudero R, Antón J, Espinós J, et al. (2011) A new rapid desensitization protocol for chemotherapy agents. J Investig Allergol Clin Immunol 21:108-112
31. Garufi C, Cristaudo A, Vanni B, Bria E, Aschelter AM, Santucci B, et al. (2003) Skin testing and hypersensitivity reactions to oxaliplatin. Ann Oncol 14:497-498
32. Rubbia-Brandt L, Tauzin S, Brezault C, Delucinge-Vivier C, Descombes P, Dousset B, Majno PE, Mentha G, Benoit T (2011) Gene expression profiling provides insights into pathways of oxaliplatin-related sinusoidal obstruction syndrome in humans. Mol Cancer Ther 10:687-696